Dr. Reddy's Laboratories Ltd. closed 17.37% short of its 52-week high of 1,420.20 rupees, which the company achieved on ...

Dr. Reddy's Laboratories Ltd. closed 15.40% below its 52-week high of 1,420.20 rupees, which the company reached on August ...

The "Sorafenib Market Report 2025" has been added to ResearchAndMarkets.com's offering.This Sorafenib market report provides a comprehensive analysis of the market's characteristics, size, and growth, ...

Epigenetic reprogramming holds promise for reversing aging, addressing cellular aging mechanisms and paving the way for ...

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, ...

Indian drugmakers Glenmark, Dr. Reddy’s Laboratories, and Emcure Pharma are in early talks to acquire the French ...

Dr. Reddy’s (RDY) commented on a news item published in Business Standard on April 13, with the heading “DRL trims workforce costs by 25% amid ...

"The cath lab was sealed on the guidelines of the district administration since all the cases are related to it and it contains all the evidence," Dr Vikrant Chauhan, a member of the team ...

Highlights,Vanguard Group Inc. significantly expanded its stake in Dr. Reddy’s Laboratories during the recent quarter.,Other firms including EverSource Wealth Advisors LLC and POM Investment ...

“Given Zydus Lifesciences and Dr Reddy’s Laboratories have high US sales exposure with ~45 per cent and 43 per cent sales contribution, we believe they are at highest risk among generics in ...